Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Breast cancer is a leading global cancer in women, with over 2 million cases in 2018, causing significant public health and economic strain.
• Limited therapeutic options exist for triple-negative breast cancers, and resistance to current treatments necessitates novel therapeutic strategies.
• Histone deacetylase inhibitors (HDACi) are small molecules targeting histone deacetylases, offering potential for chromosomal remodeling and correcting gene expression in breast cancer.

Purpose of the Study:

• To review structural insights of histone deacetylases (HDACs) and their catalytic folds.
• To guide the rational structure-based discovery of isoform-selective HDAC inhibitors for breast cancer.
• To explore a personalized medicine approach for developing targeted breast cancer therapeutics.

Main Methods:

• Review of structural data for various HDAC isoforms.
• Analysis of differential HDAC expression in breast cancer subtypes.
• Exploration of structure-based drug design principles.

Main Results:

• Identification of structural differences among HDAC isoforms.
• Understanding the landscape of HDAC expression in different breast cancer types.
• Highlighting the potential of isoform-selective inhibition.

Conclusions:

• Rational structure-based design of isoform-selective HDAC inhibitors is a promising strategy for breast cancer.
• Targeting specific HDAC isoforms based on their expression in breast cancer cells can lead to effective and selective inhibitors.
• This approach aligns with personalized medicine principles for improved breast cancer treatment.